Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.7460
-0.0062 (-0.82%)
At close: Mar 20, 2026, 4:00 PM EDT
0.7283
-0.0177 (-2.37%)
Pre-market: Mar 23, 2026, 4:00 AM EDT
Oragenics Employees
Oragenics had 5 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,968,497
Market Cap
3.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 5 | 0 | - | 3 | 2 |
| Dec 31, 2023 | 5 | -1 | -16.67% | 5 | 0 |
| Dec 31, 2022 | 6 | 1 | 20.00% | 6 | 0 |
| Dec 31, 2021 | 5 | -2 | -28.57% | 5 | 0 |
| Dec 31, 2020 | 7 | 0 | - | 7 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioRestorative Therapies | 11 |
| Purple Biotech | 9 |
| Indaptus Therapeutics | 7 |
| Galmed Pharmaceuticals | 6 |
| Enveric Biosciences | 6 |
| Adial Pharmaceuticals | 5 |
| GRI Bio | 4 |
| XORTX Therapeutics | 3 |
OGEN News
- 10 days ago - ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION - GlobeNewsWire
- 11 days ago - ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION - GlobeNewsWire
- 12 days ago - Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia - GlobeNewsWire
- 5 weeks ago - Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy - GlobeNewsWire
- 6 weeks ago - Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program - GlobeNewsWire
- 4 months ago - Oragenics Q3 2025 Shareholder Update - Business Wire
- 5 months ago - Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - Business Wire
- 5 months ago - Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development - Business Wire